Craigavon Cardiac Centre, Southern Health and Social Care Trust, Craigavon, Northern Ireland, UK.
Adv Ther. 2023 Jun;40(6):2595-2625. doi: 10.1007/s12325-023-02502-4. Epub 2023 Apr 13.
Over the course of 2022, numerous key clinical trials with valuable contributions to clinical cardiology were published or presented at major international conferences. This review seeks to summarise these trials and to reflect on their clinical context.
The authors reviewed clinical trials presented at major cardiology conferences during 2022, including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA), European Heart Rhythm Association (EHRA), Society for Cardiovascular Angiography and Interventions (SCAI), TVT-The Heart Summit (TVT) and Cardiovascular Research Technologies (CRT). Trials with a broad relevance to the cardiology community and those with potential to change current practice were included.
A total of 93 key cardiology clinical trials were identified for inclusion. Interventional cardiology data included trials evaluating the use of new generation novel stent technology and new intravascular physiology strategies such as quantitative flow ratio (QFR) to guide revascularisation in stable and unstable coronary artery disease. New trials in acute coronary syndromes and intervention focused on long-term outcomes of optimal medical therapy (OMT), revascularisation in ischaemic dysfunction and left main (LM) intervention. Structural intervention trials included latest data on optimal timing and anticoagulation strategies in transcatheter aortic valve replacement (TAVR), in addition to expanding evidence in mitral and tricuspid valve interventions. Heart failure data included trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors, iron replacement and novel drugs such as omecamtiv. Prevention trials included new data on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and polypill strategies. In electrophysiology, new data regarding optimal timing of ablative therapy for atrial fibrillation (AF) in addition to novel screening strategies were evaluated.
This article presents a summary of key clinical cardiology trials published and presented during the past year and should be of interest to both practising clinicians and researchers.
在 2022 年期间，许多对临床心脏病学有重要贡献的关键临床试验已在主要国际会议上发表或展示。本综述旨在总结这些试验并反思其临床背景。
作者回顾了 2022 年主要心脏病学会议上展示的临床试验，包括美国心脏病学会 (ACC)、欧洲经皮心血管介入学会 (EuroPCR)、欧洲心脏病学会 (ESC)、经导管心血管治疗学 (TCT)、美国心脏协会 (AHA)、欧洲心律协会 (EHRA)、心血管血管造影和介入学会 (SCAI)、TVT-心脏峰会 (TVT) 和心血管研究技术 (CRT)。本研究纳入了与心血管领域广泛相关且有可能改变当前实践的试验。
共确定了 93 项关键的心脏病学临床试验进行纳入分析。介入心脏病学数据包括评估新一代新型支架技术和新的血管内生理学策略（如定量血流比 [QFR]）在稳定和不稳定型冠状动脉疾病中指导血运重建的试验。急性冠状动脉综合征和介入的新试验侧重于最佳药物治疗（OMT）的长期结果、缺血性功能障碍和左主干（LM）介入的血运重建。结构性介入试验包括经导管主动脉瓣置换术（TAVR）中最佳时机和抗凝策略的最新数据，以及二尖瓣和三尖瓣介入的扩展证据。心力衰竭数据包括钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂、铁替代和新型药物如 omecamtiv 的试验。预防试验包括关于前蛋白转化酶枯草溶菌素/糜蛋白酶 9 (PCSK9) 抑制剂和多效药丸策略的新数据。在电生理学方面，评估了心房颤动（AF）消融治疗的最佳时机以及新的筛查策略的新数据。
本文总结了过去一年发表和展示的关键临床心脏病学试验，应该既对临床医生又对研究人员都有兴趣。
